Ozonated autohemotherapy in the treatment of comorbid insomnia

Efficacy and safety of ozonated autohemotherapy in the treatment of comorbid insomnia in patients with chronic pain

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021602

Enrollment

Unknown

Registered

2019-02-28

Start date

2019-03-01

Completion date

Unknown

Last updated

2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comorbid Insomnia

Interventions

Case series:ozone autohemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18-79 years old, male or female; 2. Patients with chronic insomnia who meet the diagnostic criteria of 2005AASM insomnia; 3. Patients with chronic pain (VAS score 1-7); 4. The patients signed the informed consent voluntarily and could cooperate with the questionnaire survey.

Exclusion criteria

Exclusion criteria: 1. pain VAS score =8; 2. obstructive sleep apnea hypopnea syndrome,restlesslegssyndrome, epilepsy; 3. shock, peptic ulcer or hemorrhage,serious cardiopulmonary complications,liver and kidney dysfunction,advanced cancer; 4. Coagulation dysfunction or abnormal platelet count and function; Mediterranean anemia; sickle-cell anemia;favism; 5. hyperthyroidism; 6. use kinase or Anti-Oxidant; 7. Pregnant or lactating women, psychosis; 8. Patients who unable to complete the related evaluation treatment or record; 9. drug and/or alcohol abuse; 10. patients receiving other similar treatment at the same time.

Design outcomes

Primary

Measure	Time frame
Pittsburgh sleep quality index;The Epworth Sleeping Scale;	—

Countries

China

Contacts

Public ContactNing Liu

Shanghai Oriental Hospital

13816327176@163.com+86 13816327176

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026